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Abstract
Background: Junctional adhesion molecule 2 (Jam2) is a member of the JAM superfamily. JAMs are localized at intercellular
contacts and participated in the assembly and maintenance of junctions, and control of cell permeability. Because Jam2 is
highly expressed in the luminal epithelium on day 4 of pregnancy, this study was to determine whether Jam2 plays a role in
uterine receptivity and blastocyst attachment in mouse uterus.
Methodology/Principal Findings: Jam2 is highly expressed in the uterine luminal epithelium on days 3 and 4 of pregnancy.
Progesterone induces Jam2 expression in ovariectomized mice, which is blocked by progesterone antagonist RU486. Jam2
expression on day 4 of pregnancy is also inhibited by RU486 treatment. Leukemia inhibitory factor (LIF) up-regulates Jam2
protein in isolated luminal epithelium from day 4 uterus, which is blocked by S3I-201, a cell-permeable inhibitor for Stat3
phosphorylation. Under adhesion assay, recombinant Jam2 protein increases the rate of blastocyst adhesion. Both soluble
recombinant Jam2 and Jam3 can reverse this process.
Conclusion: Jam2 is highly expressed in the luminal epithelium of receptive uterus and up-regulated by progesterone and
LIF via tyrosine phosphorylation of Stat3. Jam2 may play a role in the interaction between hatched blastocyst and receptive
uterus.
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Introduction
The effective reciprocal interaction between an implantation-
competent blastocyst and the receptive uterus is a prerequisite for
the success of implantation [1]. Embryo implantation starts with
the physical interaction between the apical surface of the luminal
epithelium and the trophoblast of the hatched blastocyst. Ovarian
progesterone and estrogen play key roles in these processes.
Preovulatory estrogen secretion induces epithelial cell proliferation
on day 1 of pregnancy. Progesterone from the newly formed
corpora lutea superimposed with ovarian estrogen secretion on
day 4 directs stromal cell proliferation and epithelial cell
differentiation, leading to uterine receptivity for implantation
[2]. Based on the ability to support implantation of active
blastocyst, the receptivity of an uterus can be designated as
prereceptive, receptive and nonreceptive phases [3]. The receptive
state of the uterus is defined as the limited time when the uterine
milieu is favorable to blastocyst acceptance and implantation. In
mice, the uterus becomes receptive on day 4 of pregnancy or
pseudopregnancy and proceeds to the refractory state on day 5
[3]. In humans, implantation beyond the putative window of
receptivity will lead to increased spontaneous abortions [4]. Up to
date, the molecular basis underlying receptivity regulation remains
poorly understood.
Junctional adhesion molecule (JAM) family consists of many
members with similar structural characteristic and belongs to the
immunoglobulin superfamily. There are three members of JAM
family, including JAM1 (also known as JAM-A), JAM2 (also
known as JAM-B) and JAM3 (also known as JAM-C) [5]. All of the
JAM proteins have an extracellular domain containing two
immunoglobulin-like domains, a single transmembrane segment
and a short cytoplasmic tail with a PDZ-domain-binding motif
(Phe-Leu-Val) [6]. JAM1 contains a single disulphide bridge in
each immunoglobulin-like domain, whereas JAM2 and JAM3
contain two bridges in the C2-type domain, which may impart
structural constraints [6].
Jam2 can perform its physiological functions through both
homophilic and heterophilic interactions. A recombinant protein
Jam2-Fc binding assay showed that Jam2 can form homodimers
[7]. Beside itself, Jam is also a receptor of Jam through its first Ig-
like fold [5]. Jam can interact with T, NK, and dendritic cells
through Jam3 [8]. The Jam2/3 heterodimeris contributed to
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inflammation [9]. Soluble Jam2 could dissociate soluble Jam3
homodimers to form Jam2/3 heterodimers, suggesting the
interaction between Jam2 and Jam3 is stronger than that between
Jam3 and Jam3 [10]. Jam2 can also interact with other adhesion
molecules, such as integrin a4b1 [11], which supports lymphocyte
rolling and adhesion [12].
Based on our preliminary microarray data, Jam2 was highly
expressed on days 3 and 4 of pregnancy in mouse uteri compared
to day 5 of pregnancy (our unpublished data). Considering that the
implantation window is open in this period, we assume that Jam2
may play a role during blastocyst implantation. We showed that
Jam2 is highly expressed in luminal epithelium of day 4 pregnant




Mature mice (Kunming White outbred strain) were caged in a
controlled environment (14 h light, 10 h dark). All animal
procedures were approved by the Institutional Animal Care and
Use Committee of Xiamen University (XMUEA-0080).
To induce pregnancy or pseudopregnancy, adult female mice
were mated with fertile or vasectomized males of the same strain
by co-caging, respectively (day 1=day of vaginal plug). On days 1
to 4, pregnancy was confirmed by recovering embryos from the
oviducts or uteri. The implantation sites on day 5 were identified
by i.v. injection of 0.1 ml of 1% Chicago blue dye (Sigma, St.
Louis, MO) in saline.
For RU486 treatment, pregnant mice were injected s.c. with
RU486 (25 mg/kg; Cayman Chemical, Ann Arbor, MI) in 0.2 ml
sesame oil twice at 20:00 on day 2 and 08:00 on day 3, and uteri
were collected for further analysis at 08:00 on day 4 of pregnancy.
Ovariectomized mice were treated with progesterone (1 mg/
mouse) for 1, 3, 6, 12, 24 or 48 h 15 days after ovariectomy
operation, respectively. To examine whether nuclear receptors of
progesterone are involved in steroid hormonal regulation, ovariec-
tomized mice were treated with RU486 (25 mg/kg) 1 h before
progesterone injection. RU486 was dissolved in sesame oil and
injecteds.c..Controlsreceivedthevehicleonly.Uterifromthesemice
was collected and frozen into liquid nitrogen for further analysis.
To induce delayed implantation, pregnant mice were ovariec-
tomized under ether anesthesia at 08:30–09:00 on day 4
pregnancy. Delayed implantation was maintained by daily s.c.
injection of progesterone (1 mg/mouse; Sigma) on days 5–7. To
terminate delayed implantation, progesterone-primed delayed-
implantation mice were treated with estradiol-17b (25 ng/mouse,
s.c.; Sigma) on day 7. The mice were sacrificed to collect uteri 24 h
after estrogen treatment. Delayed implantation was confirmed by
flushing blastocysts from one horn of the uterus.
Embryos at morula stage were collected at midnight on day 3 of
pregnancy. Early and late blastocysts were collected at 08:00 and
22:00 on day 4 of pregnancy, respectively.
Isolation of the luminal epithelial sheets
The luminal epithelial sheets were isolated as previously
described [13,14]. Luminal epithelium free of stromal and blood
cells, and with very limited glandular epithelial contamination was
isolated from the day 4 uteri by using mild enzymatic digestion
and mechanical method. Briefly, mouse uteri on day 4 of
pregnancy were isolated, cleaned, washed and cut into short
fragments. After a digestion in the fresh medium (HBSS with
antibiotics) containing 1.2 mg/ml dispase (Roche Diagnostics
GmbH, Mannheim, Germany) and 10 mg/ml trypsin (Sigma) for
90 min at 4uC and 30 min at room temperature, luminal
epithelium was isolated by mechanical method using a crooked
needle. The purity of isolated epithelial sheets was examined with
anti-pan-cytokeratine (a marker for epithelial cells) and anti-
vimentin (a marker for stromal cells) by Western blot, respectively.
In our isolated epithelial sheets, there were no detectable bands for
anti-vimentin antibody although a strong band was seen with anti-
pan-cytokeratine antibody (Figure S1), suggesting that isolated
epithelial sheets were nearly free of stromal cells. Uterine tissues
were washed with HBSS 3 times and cultured in Opti-medium
(Invitrogen Corp., Carlsbad, CA) for 3 h, and then these tissues
were treated with progesterone (1 mg/ml)or LIF (100 ng/ml,
Sigma). Antagonist and inhibitor were added into culture medium
1 h before progesterone or LIF treatment. The final concentra-
tions of RU486 and Stat3 inhibitor VI (S3I-201, Calbiochem)
were 1 mM and 100 mM, respectively. After treatment, luminal
epithelium sheets were collected for Western blot analysis.
Electroporation
Luminal epithelial sheets isolated as above were suspended in
800 ml Opti-Medium in a 4 mm cup and then mixed with 20 mgo f
c-Stat3 vector or pcDNA3.1 vector. Electroporation was per-
formed with BTX-830 generators according to the manufacturer’s
instruction (BTX Technologies, Hawthorne, NY) under the set of
540 V and 80 ms, and repeated 5 times at 1 Hz. Then epithelial
sheets were cultured for 18 h and collected for further analysis.
In situ hybridization
Total RNAs from the mouse day 4 uteri were reverse-
transcribed and amplified with the corresponding primers
(forward: 59-CCCAAAGAAGACTACCTCCTCC-39and reverse:
59-TTCCAGACTTCGTGTTCATTG-39). The amplified frag-
ment was cloned into pGEM-T plasmid (pGEM-T Vector System,
Promega, Madison, WI) and then amplified with the primers for
T7 and SP6 to prepare the templates for labeling sense and
antisense probes, respectively. Digoxigenin-labeled antisense or
sense cRNA probe was transcribed in vitro using digoxigenin
RNA labeling kit (Roche).
In situ hybridization was performed as described [15,16].
Briefly, uteri were cut into 4–6 mm long pieces and flash frozen in
liquid nitrogen, and then cut into 10 mm frozen sections, mounted
on 3-aminopropyltriethoxy-silane (Sigma)-coated slides and fixed
in 4% paraformaldehyde solution. All of the sections were
counterstained with 1% methyl green and the positive signal was
visualized as dark brown.
Immunohistochemistry
Frozen sections were fixed in 4% paraformaldehyde solution for
1 h, washed in PBS 3 times, and treated with 1% Triton X-100 for
20 min. After washing, sections were blocked in 10% horse serum for
1ha t3 7 uC and incubated with goat anti-mouse Jam2 IgG (R&D
system, Minneapolis, MN) at 4uC overnight. Then sections were
incubated with biotin-coupled rabbit anti-goat IgG antibody (Vector
Laboratories, Burlingame, CA) and alkaline phosphatase-coupled
streptavidin(VectorLaboratories),respectively.Thepositivesignalwas
visualized as red color by Vector Red according to the manufacturer’s
protocol (Vectastain ABC-AP kit, Vector Laboratories). Endogenous
alkaline phosphatase activity was inhibited by supplementing 1 mM
levamisole (Sigma) into Vector Red substrate solution.
For the fluorescent staining of mouse blastocysts, blastocysts
flushed from day 4 pregnant uteri were fixed in 3.7%
formaldehyde/PBS, washed in 0.1% BSA/PBS, and incubated
with anti-JAM2 antibody (R &D Systems) overnight at 4uC. After
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were incubated with FITC-conjugated rabbit anti-goat antibody
and counter-stained with DAPI for nuclei. The fluorescent signals
were examined under a confocal microscopy.
Real time RT-PCR
Total RNAs from mouse uteri were isolated using TRIzol
reagent according to the manufacturer’s instructions (Invitrogen
Corp., Carlsbad, CA). mRNAs from 10 morula, early blastocyst or
late blastocyst were extracted by Dynabeads mRNA DIRECT
TM
Kit according to the manufacturer’s instructions (Invitrogen),
respectively. cDNA was reverse transcribed using the ExScript RT
Reagents Kit (Perfect Real Time; TaKaRa, Dalian, China). For
real-time PCR, cDNA was amplified using SYBR Premix Ex Taq
(TaKaRa) according to the manufacturer’s instructions. After
analysis using the DDCt method, data were normalized to Rpl7
expression. Jam2 primer sequences used for real-time PCR were
59-ATGCTGCTGCTGCTACACTACTT-39 and 59-TGACT-




Proteins were extracted from uterine tissues with lysis buffer
[(50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% Triton X-100,
0.25% sodium deoxycholate, 1 mM NaF, 2 mM Na3VO4, and
complete protease inhibitor cocktail (Roche)]. The concentration
of proteins was measured by BCA reagent (Applygen, Beijing,
China). Proteins were run on a 10% PAGE gel and transferred
onto nitrocellulose membranes. Nitrocellulose membranes were
then blocked in 5% low-fat milk in PBST (0.1% Tween 20 in PBS)
for 1 h, and incubated with goat anti-mouse Jam2 antibody
(1:1000; AF988, R&D system), rabbit anti-glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) antibody (1:2000, sc-25778;
Santa Cruz Biotechnology), rabbit anti-total Stat3 antibody
(1:1000; #9132, Cell Signaling Technology, Boston, MA) or
rabbit anti-phosphorylation (Tyr 705) Stat3 antibody (1:2000,
#9131, Cell Signaling Technology) overnight at 4uC. After
washing in PBST, the membranes were incubated in rabbit anti-
goat antibody or goat anti-rabbit antibody conjugated with
horseradish peroxidase (1:5000, Thermo Fisher Scientific Inc.,
Waltham, MA) for 1 h, followed by three washes in PBST. The
signals were detected by an enhanced chemiluminescence kit
(Amersham Pharmacia Biotech, Arlington Heights, IL).
Adhesion assay
Recombinant mouse Jam2 protein(rJam2,50 mg/ml,988VJ,R&D
System) was coated onto the bottom of 96 well plates using ELISA-
coating buffer according to the manufacturer’s protocol (070018,
CellChip, Beijing, China) at 4uC overnight. After rJam2-coated plates
were blocked with 1% BSA at 37uCf o r2h ,3 0b l a s t o c y s t sc o l l e c t e d
from uteri 8 h after delay implantation was activated by estrogen
treatment were seeded into each well in 50 mlo fK M S Om e d i u m .
BSA was used for control. After 14 h culture, adhesion rate of
blastocyst was examined by three independent persons. Five replicates
were done and analyzed. For competitive assay, 2 mg of recombinant
Jam2 or rJam3 (1213-J3, R&D System) were added into 50 mlK M S O
medium before co-culture with blastocysts.
Results
JAM2 expression in mouse peri-implantation uterus
By in situ hybridization and immunohistochemistry, both Jam2
mRNA and protein were localized in the luminal epithelium.
There was a high level of Jam2 mRNA signals in the luminal
epithelium on days 3 and 4. The expression level of Jam2 mRNA
was much lower from day 5 compared to day 4, but higher at
implantation sites than at inter-implantation sites (Fig. 1A). Real
time RT-PCR was used to confirm Jam2 mRNA level. Jam2
mRNA level was much higher on days 3 and 4 than that at day 4
midnight and on day 5 (Fig. 1B). Because Jam2 mRNA was highly
expressed in the luminal epithelium on day 4 of pregnancy,
immunohistochemistry was performed to examine whether JAM2
protein was expressed. From 08:00 to 24:00 on day 4 of
pregnancy, JAM2 protein was detected in the luminal epithelium
and weakly seen in the glandular epithelium (Fig. 1C).
We also checked Jam2 expression during pseudopregnancy to
see whether Jam2 expression is dependent on the presence of
embryos. Jam2 mRNA expression was strongly shown in the
luminal epithelium on days 3 and 4 of pseudopregnancy (Fig. 1A).
JAM2 immunostaining was also detected in the luminal epithelium
on day 4 of pseudopregnancy (Fig. 1C).
Progesterone regulation on Jam2 expression
Because Jam2 was highly expressed on days 3 and 4 of
pregnancy and pseudopregnancy, ovariectomized mice were used
to examine whether Jam2 expression is regulated by ovarian
estrogen or progesterone. Adult ovariectomized mice were treated
with estrogen, progesterone or estrogen plus progesterone for
24 h. A high level Jam2 mRNA and protein were detected in the
luminal epithelium in progesterone group and estrogen plus
progesterone group, but not in control and estrogen group (Fig. 2A,
2B). Data from real-time RT-PCR also confirmed Jam2
upregulation in progesterone group and estrogen plus progester-
one group (Fig. 2C). To verify progesterone regulation, Jam2
expression levels following different time after progesterone
treatment were quantified by real time RT-PCR. Jam2 mRNA
level was significantly stimulated 1 h after treatment and reached
the maximal level at 6 h (Fig. 2D). JAM2 protein expression was
also up-regulated by progesterone treatment for 6, 12, and 24 h
(Fig. 2E, 2F). RU486 was used to examine whether progesterone
regulates JAM2 through progesterone receptor. Compared to
control, the expression of both Jam2 mRNA and JAM2 protein
was significantly up-regulated by progesterone treatment for 12 h,
which was abrogated by RU486 treatment (Fig. 2G–I).
Progesterone regulation on JAM2 was also determined in vitro.
Luminal epithelial sheets isolated from day 4 uteri were cultured in
Opti-Medium and treated with progesterone (1 mM). JAM2
expression in epithelial tissues was up-regulated by progesterone
treatments for 6 and 12 h compared with control (Fig. 3A, 3B).
To check if JAM2 expression in vivo was also regulated by
progesterone, pregnant mice were treated with RU486 (25 mg/kg)
twice at 2000 on day 2 and 0800 on day 3. Both Jam2 mRNA and
protein levels on day 4 were significantly down-regulated
compared to normal pregnancy (Fig. 3C–E).
JAM2 expression in luminal epithelium treated by LIF and
Stat3 inhibitor S3I-201
Since Stat3 phosphorylation at Tyr705 is at a high level in the
luminal epithelium in the day 4 morning and essential for embryo
implantation [14,17], we assume that Stat3 may transcriptionally
regulate Jam2 expression in the luminal epithelium. Therefore, we
examined effects of progesterone on Stat3 phosphorylation. In
ovariectomized mice, Stat3 phosphorylation was up-regulated
12 h after progesterone treatment, which was reversed by RU486
pre-treatment (Fig. 4A, 4B). In early pregnant mice, Stat3
phosphorylation was also inhibited by RU486 (Fig. 4C, 4D).
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injected into the uterine lumen on day 4 of pseudopregnancy.
Three hours after injection, both Jam2 expression and Stat3
phosphorylation were significantly inhibited compared to control
(Fig. 4E–G).
Vector c-Stat3 is a modified Stat3 expression vector expressing
constitutively activated Stat3 [18]. When luminal epithelia isolated
from day 4 of pregnancy were transfected with c-Stat3 vector
through electroporation, the expression level of both JAM2 and
Stat3 was up-regulated 18 h following electroporation compared
to control vector pcDNA3.1 (Fig. 4H, 4I).
Because leukemia inhibitory factor (LIF) is highly expressed in
mouse uterus on day 4 of pregnancy and essential for embryo
implantation through phosphorylating Stat3 [14,19–21], it is possible
that LIF may also regulate Jam2 expression through Stat3
phosphorylation. Then we treated luminal epithelia isolated from
day 4 uteri with LIF. Stat3 phosphorylation was up-regulated 30 min
after LIF treatment, and JAM2 expression was up-regulated at 1 h
and 3 h after LIF treatment (Fig. 5A–C). When luminal epithelia
were treated with S3I-201, an inhibitor of Stat3 phosphorylation, LIF
up-regulation on JAM2 expression was reversed (Fig. 4D–F).
Jam2 expression in preimplantation embryos
Because Jam2 could mediate cell adhesion through forming
homodimers with itself or heterodimers with Jam3 [5], real time
RT-PCR was performed to check whether Jam2 and Jam3 are
expressed in preimplantation embryos to mediate the adhesion
between blastocysts and uterus. Jam2 mRNA expression was
detected in morula, early blastocysts and late blastocysts,
respectively. The trend of Jam2 expression in these embryos was
as follows: late blastocyst.early blastocyst.morula (Fig. 6A).
Although Jam3 was also detected in these embryos, there was no
detectable difference among these embryos (data not shown).
Immunofluorescence was also performed to examine JAM2
protein in mouse blastocysts. There was no detectable green
fluorescent signal when anti-GFP antibody was used for a negative
control (Fig. 6B). When anti-JAM2 antibody was used, the positive
fluorescent signals were detected in the mouse blastocysts,
especially at the cell junction zones (Fig. 6B).
Blastocyst adhesion assay
Because Jam2 is an adhesion molecule and highly expressed in the
luminal epithelium on day 4 of pregnancy, we suppose that JAM2
m a yp l a yar o l ei nt h ea d h e s i o no fb lastocyst onto uterine luminal
epithelium. Adhesion assay was performed to verify this hypothesis.
Compared to BSA-coated plates, the rate of blastocyst adhesion on
rJAM2-coated plates was significantly higher 14 h after blastocyst
seeding (Fig. 7A). Because JAM2 can form either homodimer with
JAM2 or heterodimer with JAM3, soluble recombinant JAM2 or
JAM3 was used to challenge blastocyst adhesion in the JAM2-coated
plates. Compared to BSA, blastocyst adhesion on JAM2-coated plates
was significantly inhibited by either rJAM2 or rJAM3. However, the
inhibition by rJAM2 was stronger than rJAM3 (Fig. 7B, 7C).
Discussion
Jam2 expression in the luminal epithelium may relate to
uterine receptivity
Uterine receptivity is a restricted period when a uterus is
receptive for blastocyst attachment [22]. In mice, the pre-receptive
Figure 1. Jam2 expression in mouse uterus during early
pregnancy. (A) In situ hybridization of Jam2 mRNA. (B) Real-time RT-
PCR quantification of Jam2 mRNA. (C) JAM2 immunostaining. D1, day 1;
D2, day 2; D3, day 3; D4, day 4; D4.5-I, implantation site at day 4
midnight; D4.5-NI, inter-implantation site at day 4 midnight; D5-I,
implantation site on day 5; D5-NI, inter-implantation site on day 5; PD3,
day 3 of pseudopregnancy; PD4, day 4 of pseudopregnancy; Arrow,
embryo. Bar=150 mm.
doi:10.1371/journal.pone.0034325.g001
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receptive on day 4 of pregnancy or pseudopregnancy and proceeds
to the refractory state on day 5 [3]. Blastocyst transfer into intact
pseudopregnant mice demonstrated that the window of implan-
tation on day 4 remains open at least through 1800 h for normal
day 4 blastocysts but only up to 1400 h for dormant blastocysts
[23]. In this study, both Jam2 mRNA and protein were strongly
expressed in the luminal epithelium on days 3 and 4 of pregnancy.
Figure 2. Progesterone regulation of Jam2 in the ovariectomized mouse uteri. (A) In situ hybridization of Jam2 mRNA expression after
treatment with Oil (control), estrodiol-17b (E2), progesterone (P4) or a combination of estrogen and progesterone (E+P) for 24 h. (B) Immunostaining
of JAM2 protein after treatment with steroid hormones for 24 h. (C) Real-time RT-PCR of Jam2 mRNA expression in uteri after ovariectomized mice
were treated with Oil (control), estrodiol-17b (E2), progesterone (P4) or a combination of estrogen and progesterone (E+P) for 24 h. (D) Real-time RT-
PCR of Jam2 mRNA expression after ovariectomized mice were treated with progesterone for 1, 3, 6, 12, 24 and 48 h, respectively. (E) A representative
Western blot of Jam2 protein after ovariectomized mice were treated with progesterone for 6, 12 and 24 h, respectively. (F) The quantitative data in
Fig. 2F. (G) Real time RT-PCR of Jam2 mRNA expression after ovariectomized mice were treated with progesterone alone or progesterone plus RU486
for 12 h. Sesame oil was served as control. (H) A representative Western blot of JAM2 protein after ovariectomized mice were with progesterone
alone or progesterone plus RU486 for 12 h. P, progesterone; Oil, sesame oil. (I) The quantitative data in Fig. 2H.
doi:10.1371/journal.pone.0034325.g002
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luminal epithelium on day 4 of pregnancy. Additionally, Jam2
expression on days 3 and 4 of pseudopregnancy was similar to days
3 and 4 of pregnancy. These data suggest that Jam2 expression is
closely related to uterine receptivity and is a potential molecular
marker for uterine receptivity.
Jam2 expression in mouse uterus is regulated by
progesterone
Ovarian progesterone is essential for the success of implantation
in mammalian reproduction [24]. Preovulatory estrogen can
induce epithelial cell proliferation on day 1 of pregnancy and
progesterone from newly formed corpora lutea initiate stromal cell
proliferation from day 3. These coordinated effects of progesterone
and estrogen direct stromal cell proliferation and epithelial cell
differentiation for establishing the uterine receptivity [2].
In this study, Jam2 mRNA in ovariectomized mouse uterus was
up-regulated by a single progesterone treatment or a combination
of estrogen and progesterone. RU486, an antagonist of proges-
terone receptor, can abrogate Jam2 up-regulation by progester-
one. Furthermore, Jam2 expression was down-regulated when
pregnant mice were treated with RU486 on days 2 and 3. We also
showed that progesterone could stimulate Jam2 expression in
cultured luminal epithelial tissues. It has been reported that Jam2
was up-regulated in the luminal epithelium after ovariectomized
mice were treated with a combination of estrogen and progester-
one [25]. In humans, RU486 treatment can transform receptive
endometrium into non-receptive phase [26]. These data suggested
that progesterone might stimulate Jam2 expression in the luminal
epithelium through nuclear progesterone receptor to prepare for
receptive phase.
LIF induces Jam2 expression in luminal epithelium via
Stat3
LIF has been shown to be essential in initiating the blastocyst
implantation process because LIF-deficient female mice are unable
to accept implantation-competent blastocysts [21,27]. A single
injection of LIF into pregnant LIF-deficient females is sufficient to
induce embryo implantation and normal development to term.
Furthermore, injection of LIF could replace nidatory estrogen for
inducing implantation [28]. During early pregnancy, LIF reaches
the highest level on day 4 that just before embryo implantation
[19,20]. STAT3 can be specifically phosphorylated by LIF in the
day 4 luminal epithelium [14]. Mice carrying a mutation of gp130,
which delete all STAT-binding sites, are viable, but infertile in
female mice because of implantation failure [29]. Before embryo
implantation, functional blockade of Stat3 by injection into the
uterine lumen of a cell-permeable Stat3 peptide inhibitor can
specifically reduce embryo implantation by 70% [30]. Successful
implantation is therefore dependent on phosphorylation and
activation of Stat3 in the endometrium before implantation. In our
study, Jam2 expression pattern in the luminal epithelium during
early pregnancy is similar to that of LIF expression and
phosphorylated Stat3 [14,19,20]. Therefore, we assumed that
Jam2 expression should be regulated through LIF-Stat3 pathway.
Our in vitro culture model showed that LIF could induce Jam2
expression and Stat3 phosphorylation at Tyr 705 in cultured
luminal epithelial tissues isolated from day 4 of pregnancy. Stat3
inhibitor VI(S3I-201) is a cell-permeable and specific inhibitor for
Stat3 phosphorylation [18]. When isolated luminal epithelial
tissues from day 4 uterus were treated with S3I-201, Jam2
expression was significantly reduced. Jam2 stimulation by LIF
could be blocked by S3I-201 treatment. Furthermore, Jam2
Figure 3. Progesterone regulation of Jam2 expression. (A) A representative Western blot of JAM2 protein after luminal epithelial sheets
isolated from day 4 of pregnancy were treated in vitro with progesterone for 6 and 12 h, respectively. Progesterone was dissolved in ethanol. Ethanol
was used as control. (B) The quantitative analysis in Fig. 3A. (C) Real time RT-PCR of Jam2 mRNA expression in mouse uterus on day 4 of pregnancy
after pregnant mice were treated with RU486 (25 mg/kg) twice at 20:00 on day 2 and 08:00 on day 3. (D) A representative Western blot of JAM2 in
mouse uterus on day 4 of pregnancy after pregnant mice were treated with RU486 (25 mg/kg) twice at 20:00 on day 2 and 08:00 on day 3. (E) The
quantitative analysis in Fig. 3D.
doi:10.1371/journal.pone.0034325.g003
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with constitutive activation. By injecting Stat3 inhibitor into
uterine cavity on day 4 of pregnancy, we also found that the
expression of Jam2 mRNA and protein in mouse uterus was
reduced. Additionally, we also predicted Stat3 binding sites in the
Jam2 promoter. Therefore, LIF up-regulates Jam2 expression in
the luminal epithelium through Stat3 phosphorylation.
Furthermore, medroxyprogesterone acetate (MPA) can phos-
phorylate Stat3 at Tyr 705 and induce Stat3 nuclear localization
in C4HD epithelial cells and T47D cell line of breast cancer,
which can be reversed by RU486 [31]. In our study, progesterone
is able to induce Stat3 phosphorylation in ovariectomized mouse
uterus, which can be reversed by RU486. Stat3 phosphorylation in
day 4 uterus was also significantly inhibited when pregnant mice
were treated with RU486 on days 2 and 3. These data suggested
that progesterone up-regulates Jam2 expression through the
phosphorylation of Stat3. How progesterone regulates Stat3
phosphorylation remains to be further examined.
In the present study, we showed that Jam2 expression is up-
regulated by progesterone and LIF. Jam2 expression on days 3
and 4 pregnancy is also correlated with rising levels of endogenous
progesterone [2]. However, Jam2 expression on day 4 of
pregnancy is stronger than that on day 3 of pregnancy. Because
LIF expression on day 4 of pregnancy is mainly regulated by
preimplantation estrogen surge [19,20,32], Jam2 expression on
day 4 of pregnancy may be further stimulated by estrogen-
regulated LIF. We did find that Jam2 expression in ovariecto-
mized mouse uterus is strongly stimulated by a combination of
Figure 4. LIF and Stat3 regulation of Jam2 expression. (A) A representative Western blot of total and phosphorylated Stat3 in mouse uterus
after ovariectomized mice were treated with progesterone (P) or a combination of progesterone and RU486. (B) The quantitative data in Fig. 4A. (C) A
representative Western blot of total and phosphorylated Stat3 in mouse uterus on day 4 of pregnancy after pregnant mice were treated with RU486
(25 mg/kg) twice at 20:00 on day 2 and 08:00 on day 3. (D) The quantitative data in Fig. 4C. (E) Real time RT-PCR of Jam2 mRNA expression in mouse
uterus on day 4 of pseudopregnancy after intrauterine injection of Stat3 phosphorylation inhibitor on day 3. (F) A representative Western blot of
JAM2, total Stat3 and phosphorylated Stat3 in mouse uterus on day 4 of pseudopregnancy after intrauterine injection of Stat3 phosphorylation
inhibitor on day 3. (G) The quantitative data in Fig. 4F. (H) A representative Western blot of JAM2 and Stat3 in cultured luminal epithelium after
luminal epithelial sheets were transfected with c-Stat3 vector (c-Stat3, a continuous activated form of Stat3) and control vector (pcDNA3.1). (I) The
quantitative data in Fig. 4H.
doi:10.1371/journal.pone.0034325.g004
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expression in the luminal epithelium on day 4 of pregnancy is
stimulated by the coordinated action of both progesterone and
estrogen. However, Jam2 expression in ovariectomized mouse
uterus was not induced by estrogen. Estrogen regulation of Jam2
in mouse uterus may require progesterone priming.
JAM2 plays a role during blastocyst adhesion
In primates and rodents, embryonic implantation includes
apposition, attachment, and invasion, leading to an effective
interaction between the blastocyst and the maternal endometrium
[3]. Roles of luminal epithelium are irreplaceable during these
interactions, and many adhesion molecules in the epithelium are
crucial during the establishment of uterine receptivity.
Our results showed that both Jam2 mRNA and protein were
strongly localized in the luminal epithelium on day 4 of pregnancy,
the day of uterine receptive phase, and in blastocysts, suggesting
that Jam2 should play a role during the apposition and attachment
phases. In our in vitro adhesion assay, recombinant mouse Jam2
protein could promote the adhesion between hatched blastocysts
and Jam2-coated plates. This adhesion was partially inhibited by
soluble rJam2 and rJam3, but the inhibition by rJam2 was stronger
than rJam3. Although Jam2 could form homodimers with itself or
heterodimers with Jam3 [5], the adhesion between blastocysts and
receptive uterus should be mainly mediated by Jam2 because Jam3
was only weakly expressed in the luminal epithelium on day 4 of
pregnancy. In this study, we showed that Jam2 is stimulated by
LIF through Stat3. It is reported that LIF could increase the
Figure 5. LIF regulation of Jam2 expression. (A) A representative Western blot of JAM2, total Stat3 and phosphorylated Stat3 in luminal
epithelium after isolated luminal epithelial sheets were treated with LIF for 30 min, 1 h and 3 h, respectively. BSA was used as control. (B) The
quantitative data of JAM2 in Fig. 5A. (C) The quantitative data of phospho-Stat3 in Fig. 5A. (D) A representative Western blot of JAM2, total Stat3 and
phosphorylated Stat3 after isolated luminal epithelial sheets were treated with LIF with or without S3I for 3 h. (E) The quantitative data of JAM2 in
Fig. 5D. (F) The quantitative data of phospho-Stat3 in Fig. 5D.
doi:10.1371/journal.pone.0034325.g005
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[30]. It is possible that Jam2 may participate in the LIF-mediated
the adhesion between maternal epithelial cells and blastocysts.
Another heterophilic binding interaction involved with Jam2 is
the interaction between Jam2 and a4b1 integrin (VLA-4) [11].
VLA-4 is shown to be important in trophoblast binding to
activated endothelial cells by antibody blocking [33]. In mice, a4
subunit expression is higher in blastocyst after hatching than
before [34]. SGHPL-4, a human trophoblast-derived cell line,
expresses a4b1 integrin and can adhere with endothelial cell line,
SGHEC-7 [33]. These suggest another possibility that the
attachment between blastocysts and receptive uterus may be also
mediated by a4b1 integrin on blastocysts and Jam2 on luminal
epithelium. However, Jam2 homozygous mutant mice are fertile
and have no overt developmental defects [35]. Although Jam2
gene is indeed disrupted in homozygous mutant mice, it is still
possible that the transcript from the Jam2 mutant locus may
express certain JAM2 functions since the transcript contains a
portion of the Jam2 coding sequence [35]. It is also possible that
Jam2 loss will lead to the compensation or up-regulation of other
JAM family members.
In conclusion, Jam2 is highly expressed in the luminal
epithelium and regulated by progesterone and LIF through Stat3
phosphorylation. Jam2 may play a role in mediating the adhesion
between blastocysts and uterine luminal epithelium.
Supporting Information
Figure S1 Western blot analysis of Vimentin and pan-
cytokeratin levels in the isolated endometrial cells. Pan-
cytokeratin protein is strongly detected in the luminal epithelial
sheets, but not in the stromal cells. However, vimentin is strongly
detected in the stromal cells, but not in the luminal epithelial
sheets. b-actin was used for a loading control.
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Figure 6. Jam2 expression in mouse embryos. (A) Real time RT-
PCR of Jam2 mRNA expression in mouse embryos at morula, early (EB)
and late blastocyst (LB) stages, respectively. (B) The immunofluorescent
analysis of JAM2 protein in mouse blastocysts. Anti-GFP antibody was
used as negative control. Blastocyst nuclei were counter-stained with
DAPI (Blue staining).
doi:10.1371/journal.pone.0034325.g006
Figure 7. Blastocyst adhesion assay. (A) The adhesion rates of blastocysts on BSA or recombinant mouse Jam2 (rJam2)-coated dishes. (B) The
adhesion rates of estrogen-activated blastocysts on the rJam2-coated dishes when cultured medium was supplemented with soluble rJam2 (40 mg/
ml) or BSA. (C) The adhesion rates of estrogen-activated blastocysts on the rJam2-coated dishes when cultured medium was supplemented with
soluble rJam3 (40 mg/ml) or BSA. BSA was used as a negative control.
doi:10.1371/journal.pone.0034325.g007
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